deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03593759

Cardiac Sarcoidosis Randomized Trial (CHASM-CS-RCT)

Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Cardiac Sarcoidosis Sarcoidosis
Interventions Methotrexate Prednisone or Prednisolone
Updated 16 times since 2018 Last updated: Nov 27, 2024 Started: Jan 15, 2019 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03593759, this PHASE3 trial focuses on Cardiac Sarcoidosis and Sarcoidosis and remains actively recruiting participants. Sponsored by Canadian Institutes of Health Research (CIHR), it has been updated 16 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Aug 2023 · 21 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE3

  2. Jan 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

▶ Show 11 earlier versions

  1. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  2. Nov 2021 — Aug 2023 [monthly]

    Recruiting PHASE3

  3. May 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE3

  5. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  7. Mar 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  8. Oct 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  9. Apr 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Nov 2018 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE3

  11. Aug 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Institutes of Health Research (CIHR)
  • Ottawa Heart Institute Research Corporation
Data source: Ottawa Heart Institute Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Boston, United States , Calgary, Canada , Chiba, Japan , Columbus, United States , Fukui, Japan , Halifax, Canada , Hamilton, Canada , Kawasaki, Japan , London, Canada and 17 more locations